Hostname: page-component-77c89778f8-m8s7h Total loading time: 0 Render date: 2024-07-16T12:31:57.583Z Has data issue: false hasContentIssue false
  • English
  • Français

Is there a Relationship between Serotonin Receptor Subtypes and Selectivity of Response in Specific Psychiatric Illnesses?

Published online by Cambridge University Press:  06 August 2018

Stuart A. Montgomery  and
Naomi Fineberg
Stuart A. Montgomery*
Affiliation:
St Mary's Hospital Medical School, London
Naomi Fineberg
Affiliation:
St Mary's Hospital Medical School, London
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Extract

Identification of 5-HT receptor subtypes — 5-HT1A, 5-HT1B, 5-HT1c, 5-HT1D, 5-HT2 (possibly A and B), 5-HT3 subtypes, and possibly 5-HT4 — has encouraged the manufacture of 5-HT receptor inhibitors with greater subtype specificity. However, it appears that the receptors interact, and drugs initially thought to be specific may have multiple actions. For some conditions such as anxiety/depression, almost all receptors are implicated. Clinical studies provide clear evidence that manipulation of the 5-HT system has a role in treating depression, anxiety, obsessional illness, migraine, and eating disorders. Interactions between the various receptor subtypes make it difficult to identify specific clinical functions. The 5-HT1A receptors may be involved in aggression, anorexia, and hypotension. The 5-HT1B receptors may be involved in aggression, while the 5-HT1C receptors may play a role in central aversion systems and anxiety/depression. The role of the 5-HT1D receptors remains speculative; 5-HT2 receptors appear to be involved in depression, anxiety, appetite, sleep, vasoconstriction, and hypertension. Many drugs that are effective in treating migraine are potent 5-HT2 antagonists. 5-HT3 antagonists at high doses are effective in treating nausea and at low doses in treating anxiety. Treatment of aggression, suicidal behaviour, addiction behaviour, memory impairment, dementia, and schizophrenia with 5-HT inhibitors requires further testing.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 155 , Issue S8: SEROTONIN IN BEHAVIOURAL DISORDERS , December 1989 , pp. 63 - 69
Copyright
Copyright © Royal College of Psychiatrists, 1989 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Amsterdam, J.D., Berwish, N., Potter, L., et al (1987) Open trial of gepirone in the treatment of major depressive disorder. Current Therapeutic Research, 41, 185–193.Google Scholar
Angst, J. & Dobler-Mikola, A. (1985) The Zurich study — a prospective epidemiological study of depressive neurotic and psychosomatic syndromes IV, Recurrent and nonrecurrent brief depression. European Archives of Psychiatry and Neurological Sciences, 234, 408–416.Google Scholar
Arriaga, F., Ruiz, I., Lara, E., et al (1986) Ritanserin, an original thymosthenic for the treatment of dysthymia. A double blind placebo-controlled study. XV CINP Congress Book of Abstracts, 168.Google Scholar
Asberg, M., Traskman, L. & Thoren, P. (1976) 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Archives of General Psychiatry, 33, 1193–1197.Google Scholar
Banki, C.M. & Arato, M. (1983) Amine metabolites and neuroendocrine response related to depression and suicide. Journal of Affective Disorders, 5, 223–232.CrossRefGoogle ScholarPubMed
Bersani, G., Marini, S., Grispini, A., et al (1989) S2 Antagonism (ritanserin) and serotonin implication in dysthymia. Presented at Symposium: Serotonin from Cell Biology to Pharmacology and Therapeutics, Florence.Google Scholar
Den Boer, J.A. (1987) Serotonergic Mechanisms in Anxiety Disorders. den Haag: CIP Gegevens Koninklijke Biblioteek.Google Scholar
Den Boer, J.A. & Westenberg, G.M. (1988) Effects of serotonin and nor adrenaline uptake inhibitors in panic disorders; a double blind comparative study with fluvoxamine and maprotiline. International Clinical Psychopharmacology, 3, 59–74.Google Scholar
Bradley, P.B., Engel, G., Feniuk, W., et al (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology, 25, 563–576.CrossRefGoogle ScholarPubMed
Brown, G., Goodwin, F., Ballenger, J., et al (1979) Aggression in humans correlates with cerebrospinal fluid metabolites. Psychiatry Research, 1, 131.Google Scholar
Brown, G., Ebert, M., Goyer, P., et al (1982) Aggression, suicide and serotonin: relationships to CSF amine metabolites. American Journal of Psychiatry, 139, 741.Google ScholarPubMed
Costall, B., Domeney, A.M., Naylor, R.J., et al (1987) Effects of the 5-HT3 receptor antagonist GR380325 on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. British Journal of Pharmacology, 92, 881–894.CrossRefGoogle ScholarPubMed
Cottraux, J., Nury, A.M., Mollard, E., et al (1988) Fluvoxamine and exposure in obsessive—compulsive disorders. Presented at the Royal College of Psychiatry, London.Google Scholar
Craft, M., Ismail, I.A., Krishnamurti, D., et al (1987) Lithium in the treatment of aggression in mentally handicapped patients: a double-blind trial. British Journal of Psychiatry, 150, 685–689.CrossRefGoogle ScholarPubMed
Fabre, L.F. (1988) A study of paroxetine, imipramine and placebo in the treatment of depressed outpatients. Psychopharmacology, 96 (Suppl.), 211.Google Scholar
Fayolle, C., Filliou, M.P., Barone, P., et al (1988) 5-Hydroxytryptamine stimulates two distinct adenylate cyclase activities in rat brain: high affinity activation is related to a 5-HT, subtype different from 5-HT1A, 5-HT1B, 5-HTlc . Fundamental and Clinical Pharmacology, 2, 195–214.CrossRefGoogle Scholar
Fozard, J.R. (1989) 5-HT3 receptors. Presented at Symposium: Serotonin from Cell Biology to Pharmacology and Therapeutics, Florence.Google Scholar
Goodman, W.K., Price, L.H., Rasmussen, S.A., et al (1989) Efficacy of fluvoxamine in obsessive compulsive disorder, a double-blind comparison with placebo. Archives of General Psychiatry, 46, 36–43.CrossRefGoogle ScholarPubMed
Hamik, A. & Peroutka, S.J. (1989) 1-(m-chlorophenyl)piperazine (m-CPP) interactions with neurotransmitter receptors in the human brain. Biological Psychiatry, 25, 569–575.Google ScholarPubMed
Hartig, P.R. (1989) Molecular biology of the serotonin receptor family. Presented at Symposium: Serotonin from Cell Biology to Pharmacology and Therapeutics, Florence.CrossRefGoogle Scholar
Jacobs, E. & Wakelin, J.S. (1986) The role of serotonin in depression and suicide: are serotonin reuptake inhibitors a key? Psychopharmacology, 96 (Suppl.), 193.Google Scholar
Jenck, F., Van Delft, A.M. & Broekkamp, C.L.E. (1989) Serotonergic control of dorsal periaqueductal gray (PAG) induced aversion: a functional role for the brain 5-HT1C receptors? Presented at Symposium: Serotonin from Cell Biology to Pharmacology and Therapeutics, Florence.Google Scholar
Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment of resistant schizophrenics. Archives of General Psychiatry, 45, 789–805.CrossRefGoogle Scholar
Linnoila, M., Virkkunen, M., Scheinin, M., et al (1983) Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behaviour. Life Science, 33, 2609–2614.Google Scholar
Lopez-Ibor, J-J., Saiz-Ruiz, J. & Perez de los Cobos, J.C. (1985) Biological correlations of suicide and aggressivity in major depressions with melancholia. Neuropsychobiology, 14, 67–74.Google ScholarPubMed
Montgomery, S.A. (1980) Clomipramine in obsessional neurosis, a placebo-controlled trial. Pharmaceutical Medicine, 1, 189–192.Google Scholar
Montgomery, S.A. (1989) The efficacy of fluoxetine as an antidepressant in the short and long term. International Clinical Psychopharmacology, 4 (Suppl. 1), 113–119.Google Scholar
Montgomery, S.A. & Montgomery, D. (1982) Pharmacological prevention of suicidal behaviour. Journal of Affective Disorders, 4, 291–298.CrossRefGoogle ScholarPubMed
Montgomery, S.A., Rani, S.J., McAuley, R., et al (1981 a) The antidepressant efficacy of zimelidine and maprotiline. Acta Psychiatrica Scandinavica, 63 (Suppl. 290), 219–224.Google Scholar
Montgomery, S.A., McAuley, R. & Rani, S.J. (1981 b) A double-blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatrica Scandinavica, 63 (Suppl. 290), 314–327.Google Scholar
Montgomery, S.A., Green, M., Baldwin, D., et al (in press) Placebo-controlled studies of brief mood disturbances in personality disorders. Proceedings British Association of Psychopharmacology Congress, Galway.Google Scholar
Muijen, M., Roy, D., Silverstone, T., et al (1988) A comparative clinical trial of fluoxetine, mianserin and placebo with depressed outpatients. Acta Psychiatrica Scandinavica, 78, 384–390.Google Scholar
Perse, T.L., Greist, J., Jefferson, J.W., et al (1987) Fluvoxamine treatment of obsessive—compulsive disorder. American Journal of Psychiatry, 144, 1543–1548.Google ScholarPubMed
Van Praag, H.M., Korf, J. & Schut, D. (1973) Cerebral monoamines and depression. Archives General Psychiatry, 28, 827–831.Google Scholar
Schoeffter, P. & Hoyer, D. (1989) Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunn-Schmiedeberg's Archives of Pharmacology, 339, 675–679.Google Scholar
Smith, R.J., Davies, L.F. & Noble, J. (1989) The efficacy of zacopride in the prevention of scopolamine-induced cognitive impairment in normal young volunteers. Presented at Symposium: Serotonin from Cell Biology to Pharmacology and Therapeutics, Florence.Google Scholar
Stanley, M.S. & Mann, J.J. (1983) Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet, i, 214–216.CrossRefGoogle Scholar
Traber, J. (1989) 5-HT1A receptor partial agonists as anxiolytics. Presented at Symposium: Serotonin from Cell Biology to Pharmacology and Therapeutics, Florence.Google Scholar
Traskman, L., Asberg, M., Bertilsson, L., et al (1981) Monoamine metabolites in CSF and suicidal behaviour. Archives of General Psychiatry, 38, 751–755.Google Scholar
Tyrer, S.P., Walsh, A., Edwards, D.E., et al (1984) Factors associated with a good response to lithium in aggressive mentally handicapped subjects. Progress in Neuropsychopharmacology and Biological Psychiatry, 8, 751–755.CrossRefGoogle ScholarPubMed
De Veaugh-Geiss, J., Moro, Z.G., Landau, P., et al (1989) Treatment of adult and adolescent obsessive-compulsive disorder with anafranil. Proc. World Fed. Soc. Biol. Psych. Jerusalem.Google Scholar
De Wilde, J., Mertens, C., Fredricson Overo, K., et al (1985) Citalopram versus mianserin, a controlled double-blind trial in depressed patients. Acta Psychiatrica Scandinavica, 72, 89–96.CrossRefGoogle ScholarPubMed
Worrall, E.P., Moody, J.P. & Naylor, G.J. (1975) Lithium in nonmanic-depressives: antiaggressive effect and blood cell lithium values. British Journal of Psychiatry, 126, 464–468.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.